Significant effect of hepatitis C virus specific CTLs on viral clearance in patients with type C chronic hepatitis treated with antiviral agents

Hepatology Research

Volumn 38, Issue 5, 2008, Pages 491-500

  Satake, Shinichi ^a   Nagaki, Masahito ^a   Kimura, Kiminori ^a   Naiki, Takafumi ^a   Hayashi, Hideki ^a   Sugihara, Junichi ^b   Tomita, Eiichi ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Gifu Municipal Hospital   (Japan)

Author keywords

CTL; HCV; HLA A2tetramer; IFN

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CYTOKINE; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; HLA A2 ANTIGEN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TETRAMER; VIRUS RNA;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

EID: 42649101327     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00291.x     Document Type: Article

References (32)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244 (4902): 359-62.
2. Choo QL, Weiner AJ, Overby LR, Kuo G, Houghton M, Bradley DW. Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis. Br Med Bull 1990; 46 (2): 423-41.
3. Houghton M, Weiner A, Han J, Kuo G, Choo QL. Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. Hepatology 1991; 14 (2): 381-8.
4. Nishioka K, Watanabe J, Furuta S et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991; 67 (2): 429-33.
5. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998; 28 (1): 225-30.
6. Hu GJ, Wang RY, Han DS, Alter HJ, Shih JW. Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization. Vaccine 1999; 17 (23-24): 3160-70.
7. Schirren CA, Jung MC, Gerlach JT et al. Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology 2000; 32 (3): 597-603.
8. Cerny A, Ferrari C, Chisari FV. The class I-restricted cytotoxic T lymphocyte response to predetermined epitopes in the hepatitis B and C viruses. Curr Top Microbiol Immunol 1994; 189: 169-86.
9. Battegay M, Fikes J, Di Bisceglie AM et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995; 69 (4): 2462-70.
10. Cerny A, McHutchison JG, Pasquinelli C et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995; 95 (2): 521-30.
11. Shirai M, Arichi T, Nishioka M et al. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol 1995; 154 (6): 2733-42.
12. Kurokohchi K, Akatsuka T, Pendleton CD et al. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol 1996; 70 (1): 232-40.
13. Pereboeva LA, Pereboev AV, Morris GE. Identification of antigenic sites on three hepatitis C virus proteins using phage-displayed peptide libraries. J Med Virol 1998; 56 (2): 105-11.
14. Pereboeva LA, Pereboev AV, Wang LF, Morris GE. Hepatitis C epitopes from phage-displayed cDNA libraries and improved diagnosis with a chimeric antigen. J Med Virol 2000; 60 (2): 144-51.
15. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274 (5284): 94-6.
16. Rehermann B, Chang KM, McHutchinson J et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996; 70 (10): 7092-102.
17. Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996; 98 (6): 1432-40.
18. Parker KC, Bednarek MA, Hull LK et al. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol 1992; 149 (11): 3580-7.
19. Botarelli P, Brunetto MR, Minutello MA et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104 (2): 580-7.
20. Nijman HW, Houbiers JG, Vierboom MP et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993; 23 (6): 1215-19.
21. Caselmann WH, Serwe M, Lehmann T, Ludwig J, Sproat BS, Engels JW. Design, delivery and efficacy testing of therapeutic nucleic acids used to inhibit hepatitis C virus gene expression in vitro and in vivo. World J Gastroenterol 2000; 6 (5): 626-9.
22. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194 (10): 1395-406.
23. Altfeld M, Addo MM, Eldridge RL et al. Vpr is preferentially targeted by CTL during HIV-1 infection. J Immunol 2001; 167 (5): 2743-52.
24. Kakumu S, Aiyama T, Okumura A, Iwata K, Ishikawa T, Yoshioka K. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol 1997; 12 (6): 468-72.
25. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339 (21): 1493-9.
26. Nagaki M, Imose M, Naiki T et al. Prospective study on early virologic response to treatment with interferon alpha-2b plus ribavirin in patients with chronic hepatitis C genotype 1b. Hepatol Res 2005; 33 (4): 285-91.
27. Ballesteros AL, Franco S, Fuster D et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: Indications for the investigation of new treatment approaches. AIDS 2004; 18 (1): 59-66.
28. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 2001; 33 (4): 963-71.
29. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993; 11: 571-611.
30. Ferrari C, Chisari FV, Ribera E, Penna A, Mondelli MU. Functional modulation of hepatitis B core antigen-specific T lymphocytes by an autoreactive T cell clone. J Immunol 1988; 141 (4): 1155-60.
31. Tilg H, Vogel W, Aulitzky WE et al. Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. Transplantation 1990; 49 (6): 1074-80.
32. Su AI, Pezacki JP, Wodicka L et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99 (24): 15669-74.